CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated. Therefore, this study was conducted to evaluate the prognostic role of tumor markers and tumor marker change in patients with advanced biliary tract cancer. Materials and Methods Patients with pathologically proven metastatic or relapsed biliary tract cancer who were treated in a phase II trial of first-line S-1 and cisplatin chemotherapy were enrolled. Serum tumor markers were measured at baseline and after the first cycle of chemotherapy. Results Among a total of 104 patients, 80 (77%) had elevated baseline tumor markers (69 with CA 19-9 elevation and 40 with CEA). A decline ! 30% of the elevated tumor marker level after the first cycle of chemotherapy conferred an improved time to progression (TTP), overall survival (OS), and better chemotherapy response. Multivariate analysis revealed tumor marker decline as an independent positive prognostic factor of TTP (adjusted hazard ratio [HR], 0.44; p=0.003) and OS (adjusted HR, 0.37; p < 0.001). Subgroup analysis revealed similar results in each group of patients with CA 19-9 elevation and CEA elevation. In addition, elevated baseline CEA was associated with poor survival in both univariate and multivariate analysis. Conclusion Tumor marker decline was associated with improved survival in biliary tract cancer. Measuring tumor marker after the first cycle of chemotherapy can be used as an early assessment of treatment outcome.
Abstract
Purpose While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated. Therefore, this study was conducted to evaluate the prognostic role of tumor markers and tumor marker change in patients with advanced biliary tract cancer. Materials and Methods Patients with pathologically proven metastatic or relapsed biliary tract cancer who were treated in a phase II trial of first-line S-1 and cisplatin chemotherapy were enrolled. Serum tumor markers were measured at baseline and after the first cycle of chemotherapy. Results Among a total of 104 patients, 80 (77%) had elevated baseline tumor markers (69 with CA 19-9 elevation and 40 with CEA). A decline ! 30% of the elevated tumor marker level after the first cycle of chemotherapy conferred an improved time to progression (TTP), overall survival (OS), and better chemotherapy response. Multivariate analysis revealed tumor marker decline as an independent positive prognostic factor of TTP (adjusted hazard ratio [HR], 0.44; p=0.003) and OS (adjusted HR, 0.37; p < 0.001). Subgroup analysis revealed similar results in each group of patients with CA 19-9 elevation and CEA elevation. In addition, elevated baseline CEA was associated with poor survival in both univariate and multivariate analysis. Conclusion Tumor marker decline was associated with improved survival in biliary tract cancer. Measuring tumor marker after the first cycle of chemotherapy can be used as an early assessment of treatment outcome.
참고문헌 (23)
- Siegel R, "Cancer statistics, 2013", CA Cancer J Clin, 63, pp.11~30 (2013)
- Randi G, "Epidemiology of biliary tract cancers : an update", Ann Oncol, 20, pp.146~159 (2009)
- Jarnagin WR, "Staging, resectability, and outcome in 225patients with hilar cholangiocarcinoma", Ann Surg, 234, pp.507~517 (2001)
- Glimelius B, "Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer", Ann Oncol, 7, pp.593~600 (1996)
- Sharma A, "Best supportive care compared with chemotherapy for unresectable gall bladder cancer : a randomized controlled study", J Clin Oncol, 28, pp.4581~4586 (2010)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- 박준오, "Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review", Cancer Research and Treatment, 47(3), pp.343~361 (2015), 대한암학회[DOI]
- Kang MJ, "Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma", Acta Oncol, 51, pp.860~866 (2012)
- Kornek GV, "Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer : a randomised phase II trial", Ann Oncol, 15, pp.478~483 (2004)
- Eckel F, "Chemotherapy in advanced biliary tract carcinoma : a pooled analysis of clinical trials", Br J Cancer, 96, pp.896~902 (2007)
- 이지은, "Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer", Cancer Research and Treatment, 47(2), pp.259~265 (2015), 대한암학회[DOI]
- Takashi Sasaki, "Current status of chemotherapy for the treatment of advanced biliary tract cancer", The Korean Journal of Internal Medicine, 28(5), pp.515~524 (2013), 대한내과학회[DOI]
- Park I, "Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy", Cancer, 115, pp.4148~4155 (2009)
- Harder J, "Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer", Cancer Epidemiol Biomarkers Prev, 16, pp.2097~2100 (2007)
- Grunnet M, "Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer", Eur J Cancer, 51, pp.1381~1388 (2015)
- Kim YJ, "A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer", Ann Oncol, 19, pp.99~103 (2008)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Duffy MJ, "Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?", Clin Chem, 47, pp.624~630 (2001)
- Ballehaninna UK, "The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma : an evidence based appraisal", J Gastrointest Oncol, 3, pp.105~119 (2012)
- Sasaki T, "Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy", Cancer Chemother Pharmacol, 67, pp.847~853 (2011)
- Siqueira E, "Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis", Gastrointest Endosc, 56, pp.40~47 (2002)
- Ramage JK, "Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis", Gastroenterology, 108, pp.865~869 (1995)
- Levy C, "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis", Dig Dis Sci, 50, pp.1734~1740 (2005)